Theriva Biologics has announced promising results from the Phase 2b VIRAGE clinical trial evaluating VCN-01 (zabilugene almadenorepvec) in combination with gemcitabine/nab-paclitaxel for patients with newly diagnosed metastatic pancreatic cancer (mPDAC). The data, which will be presented by Dr. Manuel Hidalgo at the upcoming AACR Annual Meeting in April 2026, highlights the tumor response and biomarker analyses supporting an immune-mediated mechanism of action for VCN-01. Notably, patients receiving VCN-01 alongside standard chemotherapy demonstrated a significantly prolonged response duration and improved survival rates compared to those receiving chemotherapy alone.

The significance of these findings lies in their potential to reshape treatment paradigms for mPDAC, a notoriously aggressive cancer with limited therapeutic options. The trial’s results suggest that VCN-01 not only enhances the efficacy of conventional chemotherapy but also may activate the immune response against tumors, thereby addressing the critical challenge of immune evasion in pancreatic cancer. The agreement with both the FDA and EMA to initiate a pivotal Phase 3 trial further underscores the clinical relevance of these results, aiming to assess multiple doses of VCN-01 in first-line treatment settings.

The implications for the field are substantial, as this research could accelerate the development timelines for combination therapies targeting mPDAC. The positive outcomes from the VIRAGE trial may lead to a shift in how oncologists approach treatment regimens, particularly in integrating oncolytic virotherapy with existing chemotherapeutic agents. Additionally, the planned exploratory study to investigate more frequent and prolonged administration of VCN-01 could open new avenues for optimizing therapeutic strategies, ultimately enhancing patient outcomes in this challenging disease landscape.

Source: globenewswire.com